Analyst initiated coverage of Opko Health with a rating of Neutral
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/29/2026 | Outperform → Mkt Perform | Barrington Research | |
| 11/20/2025 | Neutral | Analyst | |
| 10/31/2025 | $1.60 | Buy → Hold | Jefferies |
| 4/25/2025 | Neutral | Analyst | |
| 6/29/2023 | $2.00 | Mkt Perform → Outperform | Barrington Research |
| 12/15/2022 | $3.00 | Buy | H.C. Wainwright |
| 1/24/2022 | Outperform → Market Perform | Barrington Research |
4 - OPKO HEALTH, INC. (0000944809) (Issuer)
4 - OPKO HEALTH, INC. (0000944809) (Issuer)
3 - OPKO HEALTH, INC. (0000944809) (Issuer)
Multispecific antibody conjugated LNP/mRNA platform enables in vivo T-cell engineering and systemic B-cell depletion in animal models Data will be presented at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting WESTON, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ:OPK), will announce preclinical data demonstrating the in vivo generation of CAR-T cells and deep systemic B-cell depletion achieved with its MDX3001 candidate in animal models. The data, generated using ModeX's CD3xCD28 antibody-conjugated lipid nanoparticle (LNP)/mRNA platform, will be presented at the ASGCT 2026 Annual Meeting, being held May 11-15 in Bo
MIAMI, April 30, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) (OPKO) today announced that its subsidiary EirGen Pharma Limited (EirGen) has entered into an amendment to its agreement with Nicoya Therapeutics (Macau) Limited, an affiliate of Nicoya Therapeutics (Nicoya), which grants OPKO an equity stake in Nicoya and reinforces Nicoya's commitment to commercialize RAYALDEE® in Greater China. RAYALDEE is approved in Macau, and the companies expect regulatory approvals in China and related territories in 2027. In June 2021, EirGen and Nicoya entered into an agreement for the development and commercialization in Greater China of RAYALDEE® for the treatment of secondary hyperparath
ELMWOOD PARK, N.J., April 30, 2026 (GLOBE NEWSWIRE) -- BioReference® Health LLC, an OPKO Health, Inc. company and a trusted provider of diagnostic testing in the United States, today announced the launch of BioReference DirectTM, a new digital health platform designed to give consumers direct access to high-quality laboratory testing. Leveraging 45 years of laboratory testing expertise, along with an established footprint of patient service centers across New York and New Jersey, BioReference is expanding its capabilities to deliver a seamless, end-to-end digital experience. BioReference Direct enables individuals to select from a menu of available laboratory tests online, all supported b
4 - OPKO HEALTH, INC. (0000944809) (Issuer)
4 - OPKO HEALTH, INC. (0000944809) (Issuer)
4 - OPKO HEALTH, INC. (0000944809) (Issuer)
Barrington Research downgraded Opko Health from Outperform to Mkt Perform
Analyst initiated coverage of Opko Health with a rating of Neutral
Jefferies downgraded Opko Health from Buy to Hold and set a new price target of $1.60
DEFA14A - OPKO HEALTH, INC. (0000944809) (Filer)
DEFA14A - OPKO HEALTH, INC. (0000944809) (Filer)
DEF 14A - OPKO HEALTH, INC. (0000944809) (Filer)
WESTON, Mass., Sept. 23, 2024 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health, Inc. (NASDAQ:OPK) company, today announced the appointment of Giovanni Abbadessa, M.D., Ph.D. as Chief Medical Officer, a newly created position. Dr. Abbadessa has over two decades of experience in drug development, including most recently as Vice President at Sanofi, where he provided executive leadership for advancing oncology assets. "Dr. Abbadessa's deep experience in leading early-stage oncology development makes him the ideal fit to steer development of our multispecific antibodies for cancer and other clinical indications," said Dr. Gary Nabel, co-founder, President and CEO of ModeX Thera
NEW YORK, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Shareholders of Talkspace, Inc. (NASDAQ:TALK) today elected Jon Cohen, M.D., to the virtual behavioral healthcare company's board of directors and approved all other shareholder proposals during the company's first Annual Meeting of Stockholders. Dr. Cohen is prior Executive Chairman and Chief Executive Officer of BioReference Laboratories and Senior Vice President of OPKO Health (NASDAQ:OPK). Dr. Cohen brings 30 years of healthcare industry strategy and operating experience to Talkspace's board of directors. He succeeds Jeffrey Crowe as an independent Class I Director with a term expiring in 2025. Additionally, the Company's board appointed C
MIAMI, June 22, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) today announced the appointment of Katherine Stueland as President and Chief Executive Officer of GeneDx, Inc., the global genomics subsidiary of OPKO's BioReference Laboratories. Ms. Stueland joins GeneDx from Invitae Corporation (NYSE:NVTA), where she served most recently as Chief Commercial Officer, establishing the corporate brand as Invitae evolved from a private company to a public entity with a market capitalization exceeding $6 billion. "We're thrilled to have Katherine lead the team at GeneDx, which has served clinicians and patients for more than two decades with novel and differentiated technologies for di
MIAMI, April 28, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) (OPKO) reports business highlights and financial results for the three months ended March 31, 2026. Highlights from the first quarter of 2026 and recent weeks included the following: Initiated and completed first dose cohort of MDX2301 Phase 1 clinical trial for the prevention of COVID-19. MDX2301 is a tetravalent bispecific antibody that neutralizes all known variants of SARS-CoV-2 and also has the potential to delay resistance by emerging variants. The Phase 1 clinical trial (NCT07445971) is evaluating the safety, pharmacokinetics and tolerability of MDX2301 administered via different routes in healthy volunteers
MIAMI, April 21, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) plans to report operating and financial results for the three months ended March 31, 2026 after the close of the U.S. financial markets on Tuesday, April 28, 2026. OPKO's senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on April 28th beginning at 4:30 p.m. Eastern time. CONFERENCE CALL & WEBCAST INFORMATION OPKO encourages participants to pre-register for the conference call using this link. Callers who pre-register will receive a unique PIN to gain immediate access to the call and bypass the live operator. Participants
MIAMI, Feb. 26, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) (OPKO) reports business highlights and financial results for the three and 12 months ended December 31, 2025, and introduces financial guidance for the first quarter and full year 2026. Highlights from the fourth quarter of 2025 and recent weeks include the following: Entered into a research collaboration with Regeneron Pharmaceuticals to develop multispecific antibodies. This new partnership leverages ModeX's MSTAR technology platform with Regeneron's proprietary binders to develop single molecule candidates that target multiple distinct biological pathways in several clinical indications. ModeX received an upfront
SC 13D/A - OPKO HEALTH, INC. (0000944809) (Subject)
SC 13G - OPKO HEALTH, INC. (0000944809) (Subject)
SC 13G/A - OPKO HEALTH, INC. (0000944809) (Subject)